Bharat Biotech’s intranasal vaccine for COVID-19

Print Friendly, PDF & Email

Recently, Bharat Biotech has completed the Phase II trial of the intranasal (injected through the nose) Covid vaccine, BBV 154.

It is a novel adeno virus carrier vaccine.

Profit:

Other vaccines only produce antibodies, but intranasal vaccines produce antibodies as well as reduce the risk of infection.

Easy dispensing – no syringe and needle required.

Additional immune response:

  • In addition to immunity in the blood, it also activates the immunity of cells found in the tissues of the nose and mouth and lungs.
  • Only a small amount of this will usually be needed, usually 0.1 ml.

Source – PIB

Download Our App

MORE CURRENT AFFAIRS

IAS Online Coaching

Login to your account

Daily Current Affairs Quiz | Current Affairs | How to Prepare For UPSC Interview | CSAT Strategy For UPSC | GK Question for UPSC | UPSC quiz in hindi | Civil Services Coaching

Want to Purchase Best Study Material For UPSC ?

All the books are in hard copy we will deliver your book at your given address

Open chat
1
Youth Destination IAS . PCS
To get access
- NCERT Classes
- Current Affairs Magazine
- IAS Booklet
- Complete syllabus analysis
- Demo classes
https://online.youthdestination.in/